Immuneering Corp Stock Fundamentals
| IMRX Stock | USD 1.69 0.07 3.98% |
Immuneering Corp fundamentals help investors to digest information that contributes to Immuneering Corp's financial success or failures. It also enables traders to predict the movement of Immuneering Stock. The fundamental analysis module provides a way to measure Immuneering Corp's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Immuneering Corp stock.
At this time, Immuneering Corp's Net Interest Income is fairly stable compared to the past year. Interest Income is likely to rise to about 4.1 M in 2025, whereas Selling General Administrative is likely to drop slightly above 10.2 M in 2025. Immuneering | Select Account or Indicator |
Immuneering Corp Company Current Valuation Analysis
Immuneering Corp's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Immuneering Corp Current Valuation | 4.82 M |
Most of Immuneering Corp's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Immuneering Corp is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Immuneering Current Valuation Historical Pattern
Today, most investors in Immuneering Corp Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Immuneering Corp's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current valuation growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Immuneering Corp current valuation as a starting point in their analysis.
Immuneering Corp Current Valuation |
| Timeline |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Immuneering Corp has a Current Valuation of 4.82 M. This is 99.97% lower than that of the Biotechnology sector and 99.9% lower than that of the Health Care industry. The current valuation for all United States stocks is 99.97% higher than that of the company.
Immuneering Corp Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Immuneering Corp's current stock value. Our valuation model uses many indicators to compare Immuneering Corp value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Immuneering Corp competition to find correlations between indicators driving Immuneering Corp's intrinsic value. More Info.Immuneering Corp is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, Immuneering Corp's Return On Equity is fairly stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Immuneering Corp's earnings, one of the primary drivers of an investment's value.Immuneering Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Immuneering Corp's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Immuneering Corp could also be used in its relative valuation, which is a method of valuing Immuneering Corp by comparing valuation metrics of similar companies.Immuneering Corp is currently under evaluation in current valuation category among its peers.
Immuneering Corp Current Valuation Drivers
We derive many important indicators used in calculating different scores of Immuneering Corp from analyzing Immuneering Corp's financial statements. These drivers represent accounts that assess Immuneering Corp's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Immuneering Corp's important valuation drivers and their relationship over time.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Enterprise Value | 412.3M | 356.1M | 60.2M | 153.9M | 177.0M | 315.5M |
Immuneering Fundamentals
| Return On Equity | -0.72 | ||||
| Return On Asset | -0.42 | ||||
| Current Valuation | 4.82 M | ||||
| Shares Outstanding | 31.05 M | ||||
| Shares Owned By Insiders | 27.81 % | ||||
| Shares Owned By Institutions | 13.99 % | ||||
| Number Of Shares Shorted | 2.16 M | ||||
| Price To Book | 0.89 X | ||||
| Price To Sales | 563.62 X | ||||
| Revenue | 455 | ||||
| Gross Profit | 158.83 K | ||||
| EBITDA | (58.06 M) | ||||
| Net Income | (53.47 M) | ||||
| Cash And Equivalents | 128.1 M | ||||
| Cash Per Share | 4.85 X | ||||
| Total Debt | 4.46 M | ||||
| Debt To Equity | 0.04 % | ||||
| Current Ratio | 33.99 X | ||||
| Book Value Per Share | 1.86 X | ||||
| Cash Flow From Operations | (48.97 M) | ||||
| Short Ratio | 0.46 X | ||||
| Earnings Per Share | (1.97) X | ||||
| Target Price | 11.92 | ||||
| Number Of Employees | 66 | ||||
| Beta | -0.37 | ||||
| Market Capitalization | 51.23 M | ||||
| Total Asset | 102.58 M | ||||
| Retained Earnings | (163.26 M) | ||||
| Working Capital | 81.24 M | ||||
| Net Asset | 102.58 M |
About Immuneering Corp Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Immuneering Corp's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Immuneering Corp using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Immuneering Corp based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 4.7 M | 4.1 M | |
| Total Revenue | 409.50 | 389.03 | |
| Cost Of Revenue | 687.7 K | 732.6 K | |
| Stock Based Compensation To Revenue | 11.54 | 12.12 | |
| Sales General And Administrative To Revenue | 44.32 | 46.53 | |
| Research And Ddevelopement To Revenue | 102.98 | 108.13 | |
| Capex To Revenue | 2.11 | 2.21 | |
| Revenue Per Share | 0.01 | 0.01 | |
| Ebit Per Revenue | (187.75) | (178.36) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Immuneering Stock Analysis
When running Immuneering Corp's price analysis, check to measure Immuneering Corp's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immuneering Corp is operating at the current time. Most of Immuneering Corp's value examination focuses on studying past and present price action to predict the probability of Immuneering Corp's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immuneering Corp's price. Additionally, you may evaluate how the addition of Immuneering Corp to your portfolios can decrease your overall portfolio volatility.